<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339689</url>
  </required_header>
  <id_info>
    <org_study_id>1042-0700</org_study_id>
    <nct_id>NCT01339689</nct_id>
  </id_info>
  <brief_title>Ganaxolone in Posttraumatic Stress Disorder (PTSD)</brief_title>
  <official_title>A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled,
      15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress
      Disorder (PTSD). Up to 120 subjects will be enrolled and randomized to receive either
      ganaxolone or placebo for 6 weeks. After 6 wks of randomized treatment all subjects will
      continue for 6 wks on ganaxolone. The aim of the study is to assess the efficacy of
      ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment
      using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to
      evaluate the safety and tolerability of ganaxolone in the PTSD population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician-Administered PTSD Scale (CAPS) scores.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-I scores</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>non-active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>200-600 mg bid, capsules, up to 12 weeks</description>
    <arm_group_label>Ganaxolone</arm_group_label>
    <other_name>GNX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules, bid, up to 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Veteran or civilian adult outpatients 18-55 years of age, with primary PTSD as defined
             by DSM-IV for at least 6 months

          -  Must be in general good health-confirmed by medical history, physical examination, and
             screening laboratory results

          -  Negative urine drug screen for drugs of abuse

          -  Negative urine pregnancy test for females of childbearing potential

          -  Sexually active subjects are required to use a medically acceptable form of birth
             control

        Key Exclusion Criteria

          -  Clinically unstable medical disease; progressive CNS disorder/disease; history of
             seizures (except childhood febrile seizure); moderate or severe traumatic brain injury
             (TBI)

          -  Females who are pregnant or currently breast feeding

          -  Current or past psychotic disorder, bipolar Type I disorder, or dementia

          -  Subjects with recent drug abuse or dependency (excluding nicotine and caffeine)

          -  Subjects unwilling to comply with the required alcohol prohibition during the trial

          -  Current suicidal or homicidal ideation necessitating intervention, and those with a
             history of suicide attempt in the past 10 years

          -  Subjects with pending litigation related to the traumatic event

          -  Subjects who are unwilling to withhold grapefruit or grapefruit juice for the duration
             of the study

          -  Subjects receiving psychotherapy without a stable paradigm for at least 3 months

          -  Non-English speaking subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine E Marx, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center and Durham VA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Rasmusson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University School of Medicine Research Affiliate, National Center for PTSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System/ University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington DC VA Medical Center/ Uniformed Services University of the Health Services</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare Services/ Spaulding Rehabilitation Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester VA Medical Center/ Dartmouth College</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center /Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center/ University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston VA Medica Center/ Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center/ Dartmouth College</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <disposition_first_submitted>June 8, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 21, 2015</disposition_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Posttraumatic Stress Disorder</keyword>
  <keyword>pharmacotherapy</keyword>
  <keyword>ganaxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

